Chong Kun Dang Holdings Corp. (KRX:001630)
44,900
+250 (0.56%)
At close: Nov 4, 2025
Chong Kun Dang Holdings Revenue
Chong Kun Dang Holdings had revenue of 242.18B KRW in the quarter ending June 30, 2025, a decrease of -2.52%. This brings the company's revenue in the last twelve months to 948.12B, up 0.22% year-over-year. In the year 2024, Chong Kun Dang Holdings had annual revenue of 957.75B with 8.86% growth.
Revenue (ttm)
948.12B
Revenue Growth
+0.22%
P/S Ratio
0.23
Revenue / Employee
25.62B
Employees
37
Market Cap
214.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 957.75B | 77.97B | 8.86% |
| Dec 31, 2023 | 879.78B | -29.18B | -3.21% |
| Dec 31, 2022 | 908.96B | -17.01B | -1.84% |
| Dec 31, 2021 | 925.98B | 67.86B | 7.91% |
| Dec 31, 2020 | 858.12B | 137.47B | 19.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |